Abstract
For patients undergoing treatment for cancer-induced pain, the identification and evaluation of pharmacogenetic variability may improve outcomes. Metabolism of opioids and other analgesic agents is influenced by patient-specific variables and drug–drug interactions, which often pose clinical challenges. Consultation with a clinical pharmacist or pharmacogenetics specialist is recommended to aid in the interpretation and evaluation of pharmacogenetic test results. The current NCCN Guidelines for Adult Cancer Pain provide pharmacogenetic considerations and recommendations for the treatment and supportive care of this population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the National Comprehensive Cancer Network
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
